New antidepressant approvedInforms that Effexor (venlafaxine hydrochloride) received Food and Drug Administration (FDA) approval on December 28, 1993 as a treatment for depression. Similarities of Effexor to tricyclic antidepressants; Cautions to physicians.Fd...
If and when FDA approved, it’ll be interesting to determine whether some of these medications provide a sustained (i.e. long-term) antidepressant effect without tolerance onset (e.g. the need for dosage increases after a year or two because the “antidepressant stopped working”). Because mo...
Recommendations FDA Approves Vortioxetine for Major Depression CommentsWhat to Read Next on Medscape Special Coverage: COVID-19 Latest Perspective Guidelines Drugs & Diseases Global Coverage Additional Resources Business of Medicine Pharmacogenomic Testing for Antidepressants Could Save Time, Money Infographic...
FDA panel urges “black box” warning for antidepressants A blue-ribbon scientific advisory panel has urged the US Food and Drug Administration (FDA) to include "black box" warnings on selective serotonin reuptake inhibitors (SSRIs) advising of the increased risk of suicidal behaviour among ped.....
Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002. OBJECTIVE: This study aimed to track the inclusion of women in clinical trials for new drugs approved by the Food and Drug Administration (FDA) between 200... Y Yang,AS Carlin...
The drug will have a boxed warning about the risk of suicidal thoughts associated with antidepressants like Bupropion. Additional risks include the possibility of seizures, as well as increased blood pressure and heart rates. The FDA recommends physicians who prescribe the drug evaluate their patients...
Dozens of antidepressants were approved in the decades that followed, including Eli Lilly’s “blockbuster” drug, Prozac, in 1987.1 Chittaranjan Andrade, MD, a professor and head of the Department of Psychopharmacology at the National Institute of Mental Health and Neurosciences in Bangalore, India...
FDA previously granted Priority Review for the sNDA, a designation for a drug application that, if approved, would represent a significant improvement in the safety and/or effectiveness of the treatment, diagnosis, or prev...
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age. The FDA prev
Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for use in the treatment of agitation associated with dementia